News
BLRX
0.2334
+4.76%
0.0106
Weekly Report: what happened at BLRX last week (1216-1220)?
Weekly Report · 3d ago
Weekly Report: what happened at BLRX last week (1209-1213)?
Weekly Report · 12/16 10:22
Weekly Report: what happened at BLRX last week (1202-1206)?
Weekly Report · 12/09 10:20
Weekly Report: what happened at BLRX last week (1125-1129)?
Weekly Report · 12/02 10:20
JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX)
TipRanks · 11/26 17:45
BioLineRx Reports Strategic Moves in Q3 2024
TipRanks · 11/26 03:55
BioLine RX Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/25 17:23
BioLine RX Price Target Cut to $9.00/Share From $21.00 by HC Wainwright & Co.
Dow Jones · 11/25 17:23
HC Wainwright & Co. Maintains Buy on BioLine Rx, Lowers Price Target to $9
Benzinga · 11/25 17:13
BioLineRx price target lowered to $9 from $21 at H.C. Wainwright
TipRanks · 11/25 17:00
BRIEF-BioLineRx Reports Q3 2024 Financial Results
Reuters · 11/25 14:42
BioLineRx Secures Key Deals to Boost Shareholder Value
TipRanks · 11/25 12:31
Options Volatility and Implied Earnings Moves Today, November 25, 2024
TipRanks · 11/25 12:05
BioLineRx GAAP EPS of $0.00 beats by $0.07, revenue of $4.94M misses by $0.35M
Seeking Alpha · 11/25 12:04
BioLine Rx Q3 2024 GAAP EPS $(0.00) Beats $(0.05) Estimate, Sales $4.94M Miss $5.29M Estimate
Benzinga · 11/25 12:02
Options Volatility and Implied Earnings Moves This Week, November 25 – November 29, 2024
TipRanks · 11/25 12:00
BIOLINERX Q3 NET INCOME USD -5.8 MILLION
Reuters · 11/25 12:00
BIOLINE RX LTD: TO EVALUATE ADDITIONAL ASSET OPPORTUNITIES IN 2025
Reuters · 11/25 12:00
BIOLINE RX LTD QTRLY EPS $-0.00
Reuters · 11/25 12:00
Weekly Report: what happened at BLRX last week (1118-1122)?
Weekly Report · 11/25 10:16
More
Webull provides a variety of real-time BLRX stock news. You can receive the latest news about Biolinerx through multiple platforms. This information may help you make smarter investment decisions.
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.